SCA
PRTK

Secor Capital Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Secor Capital Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,245
Closed -$390K – 602
2017
Q1 		$390K Sell
20,245
-16,440
-45% -$259K 0.04% 369
2016
Q4 		$565K Sell
36,685
-21,421
-37% -$278K 0.07% 324
2016
Q3 		$756K Buy
+58,106
New +$770K 0.08% 295

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Secor Capital Advisors's PRTK Position: Q2 2017 in Review

Secor Capital Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2017, closing a stake of 20,245 shares — an estimated $390K sold.

Secor Capital Advisors first reported a position in PRTK in Q3 2016 and held it in 3 quarters. The position peaked at $756K in Q3 2016. 119 funds tracked by Wall St. Rank hold PRTK as of Q2 2017.

  • Secor Capital Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 20,245 Paratek Pharmaceuticals, Inc. shares in Q2 2017, an estimated $390K.
  • Secor Capital Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Secor Capital Advisors's Paratek Pharmaceuticals, Inc. position peaked at $756K in Q3 2016.
  • 119 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2017.

Based on Secor Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.